ClinicalTrials.gg
RecruitingNCT06721299Target FSHDUpdated Feb 25, 2026

Clenbuterol to Target DUX4 in FSHD

A Phase 1 interventional study of Clenbuterol in Muscular Dystrophy, Facioscapulohumeral, sponsored by Jeffrey Statland. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Jeffrey Statland · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Planned enrollment
13th of 21
30 · median 51
Started
2025
with 4 others
Phase 1
3 of 32
2 open now
Primary completion
2028-02
later than 4 of 12 live
Registered
25th of 32
by date

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 4 of the 12 other live ones, and was the 25th registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.

Read the detailed description

Clenbuterol is an EMA approved drug for COPD that three independent patient derived screens identified as suppressing DUX4 expression in cultured FSHD muscle. Prior clinical studies with related beta2-agonists showed some activity in FSHD but did not meet their primary endpoint, although the prior studies would likely have been designed differently with current knowledge. Target FSHD is a 6-month open-label multiple ascending dose study of clenbuterol for safety and tolerability to determine the best dose for a future trial of efficacy. In addition, this study will collect secondary outcome data on muscle function, MRI changes (lean muscle volume, fat infiltration, STIR-rating) and molecular markers of disease activity (histopathology and pre-determined baskets of DUX4-target, inflammation, and ECM genes) at the beginning and end of the study to assess and power their utility as measures of drug activity in a future interventional study of efficacy.

03

Conditions studied

  • Muscular Dystrophy, Facioscapulohumeral

Keywords

  • FSHD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation
  • between 18 and 75 years of age
  • with a clinical severity score between 0 and 10
  • Able to walk 30ft without support of another person
  • Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle
  • willing and able to provide
  • agree to follow the requirement for duration of the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant or planning to become pregnant during the conduct of the study
  • have a poorly controlled medical condition
  • Were involved in a study of an experimental agent within 3 months of enrollment
  • Are taking beta-blockers or anabolic agent or potassium wasting diuretics
  • Are taking or are planning to take a GLP-1 Agonist during trial
  • have any condition or which would interfere with testing or preclude use of beta-agonist
  • Are taking blood thinners or medications which make a needle muscle contra-indicated
  • Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose
  • Are taking any medications or therapies with a contraindication to Clenbuterol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Clenbuterol Cohort 1

    20 mcg taken orally twice daily

    Drug: Clenbuterol

  • Experimental
    Clenbuterol Cohort 2

    40 mcg taken orally twice daily

    Drug: Clenbuterol

  • Experimental
    Clenbuterol Cohort 3

    60 mcg taken orally twice daily

    Drug: Clenbuterol

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of Clenbuterol-related adverse reactions

    Patient report and medical records will be used to document adverse events and severe adverse events. Adverse events and severe adverse events will be assessed by the investigator and reported as needed for safety.

    Time frame: from baseline to 6 month visit

  2. change in heart rate

    Review of Vitals

    Time frame: from Month 1 to Month 6 visit

  3. change in blood pressure

    Review of Vitals

    Time frame: from Month 1 to Month 6 visit

  4. Safety Lab Potassium (K)

    patient safety measured by potassium for signs of hypokalemia

    Time frame: Baseline to month 6 visit

  5. Safety Lab Glucose

    Patient safety measured by blood glucose abnormalities

    Time frame: Baseline to month 6 visit

  6. Tolerability of 3 doses of clenbuterol in sequential cohorts

    Tolerability will be defined as completing an arm without any clenbuterol related adverse events causing someone to withdraw

    Time frame: from baseline to 6 month visit

  7. Safety ECG

    Looking for sympathomimetic side effects such as cardiac arrhythmias

    Time frame: from Month 1 to Month 6 visit

  8. Safety Lab Creatine kinase (CK)

    Patient Safety measured by creatine kinase abnormalities

    Time frame: Baseline to Month 6 visit

Secondary outcomes

  1. MRI

    MRI measurements are considered gold standard for lean muscle volume measurement and disease biomarkers (fat volumes, fat faction, and STIR+ presence) that may be modulated by treatment. In addition, we will include analysis to help make needle biopsy based on STIR and quantitative fat fraction more efficient with higher yield using standard fiducial markings and body landmarks.

    Time frame: Screening to Month 6 Visit

  2. Muscle Biopsy for RNA sequencing

    change in a set of DUX4-regulated genes as measured in muscle using RNA sequencing. goal is to better understand the molecular changes in muscle tissue effected by the use of Clenbuterol.

    Time frame: Baseline and Month 6

  3. FSHD-COM

    An 18-item evaluator administered instrument comprised of individually validated functional motor task.the body regions assessed match areas of importance identified by patients and include leg function; shoulder and arm function; trunk function, hand function; and functional balance

    Time frame: Screening to Month 6 Visit

  4. Manual Muscle Testing (MMT)

    a modified Medical Research Council 13-point scale with standardized positions for each muscle will help look at subject's change in strength over time.

    Time frame: Screening to Month 6 Visit

  5. Quantitative Muscle Testing (QMT)

    Will test 5 bilateral muscles using a fixed myometry testing system with a force transducer attached by an inelastic strap to a metal frame, This will help us assess subjects change in strength

    Time frame: Screening to Month 6 Visit

  6. Patient Reported Outcome Measurement Information System-57 (Promis57)

    The PROMIS57 is an instrument developed by the NIH which generates scores for physical function, and the impact of physical limitations on daily life. 57 questions are summed into a total score, which is transformed into a normalized t-score with 50 representing normal, and lower scores representing increasing disability.

    Time frame: Screening to Month 6 Visit

  7. FSHD Rasch-built overall disability scale (FSHD-RODS)

    The FSHD-RODS is a questionnaire about the relationship between daily activities and health. 32 questions are are constructed using a modern clinimetric technique, the Rasch analysis, which by ordering the items in increasing difficulty, allows for the calculation of the sum of item scores to achieve a total score. Answers provide information about how FSHD affects daily and social activities and to what degree participants are able to perform usual activities.

    Time frame: Screening to Month 6 Visit

  8. Upper Extremity Functional Index (UEFI)

    This index measures upper extremity dysfunction. 20 questions are combined into a total score, the score is transformed into a normalized score with 80 representing normal, and lower scores representing increasing disability.

    Time frame: Screening to Month 6 visit

  9. Clinical Global Impression of Severity and Change (CGI-S and CGI-C)

    Is a rating scale that measures symptom severity and change in severity in response to treatment in clinical trials.

    Time frame: Screening to Month 6 visit

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Feb 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Dec 6, 2024
StartActual
Jun 25, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Jul 2028
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06721299
Lead sponsor
Jeffrey Statland
Responsible party
Jeffrey Statland (Professor of Neurology, University of Kansas Medical Center) — Sponsor-investigator
First posted
Dec 6, 2024
Start date
Jun 25, 2025
Primary completion
Feb 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Feb 25, 2026

Study contacts

Rebecca Clay
Contact
rclay@kumc.edu
9139459936

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clenbuterol

Start the discussion